Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GBIO Generation Bio	$0.35 +3.0%	$0.38	$0.30 ▼ $3.65	$22.99M	2.59	395,068 shs	676,584 shs
HRMY Harmony Biosciences	$32.09 -0.1%	$33.20	$26.47 ▼ $41.61	$1.85B	0.83	631,656 shs	287,680 shs
MDGL Madrigal Pharmaceuticals	$298.49 -0.6%	$291.28	$200.63 ▼ $377.46	$6.64B	-1.05	359,776 shs	108,674 shs
RVNC Revance Therapeutics	$3.65	$3.65	$2.71 ▼ $6.65	$381.02M	0.9	3.64 million shs	N/A
STOK Stoke Therapeutics	$11.49 -0.6%	$10.43	$5.35 ▼ $16.15	$626.77M	1.14	672,891 shs	185,804 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GBIO Generation Bio	0.00%	+15.85%	-4.81%	-6.58%	-85.74%
HRMY Harmony Biosciences	0.00%	+0.34%	-8.39%	+9.67%	+3.88%
MDGL Madrigal Pharmaceuticals	0.00%	-0.75%	+8.90%	-5.06%	+9.87%
RVNC Revance Therapeutics	0.00%	0.00%	0.00%	0.00%	+36.19%
STOK Stoke Therapeutics	0.00%	-1.25%	+5.56%	+93.35%	-9.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GBIO Generation Bio	2.9667 of 5 stars	3.5	3.0	0.0	0.0	3.3	1.3
HRMY Harmony Biosciences	4.7951 of 5 stars	4.6	1.0	0.0	2.8	3.3	4.4
MDGL Madrigal Pharmaceuticals	4.0894 of 5 stars	3.4	0.0	4.6	2.2	3.3	0.6
RVNC Revance Therapeutics	2.7618 of 5 stars	3.1	0.0	4.7	0.0	1.7	0.6
STOK Stoke Therapeutics	3.9352 of 5 stars	3.6	0.0	4.8	1.8	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GBIO Generation Bio	3.00	Buy	$7.33	2,007.28% Upside
HRMY Harmony Biosciences	3.13	Buy	$53.63	67.11% Upside
MDGL Madrigal Pharmaceuticals	2.89	Moderate Buy	$420.63	40.92% Upside
RVNC Revance Therapeutics	2.13	Hold	$8.45	131.51% Upside
STOK Stoke Therapeutics	3.29	Buy	$23.20	102.00% Upside

Current Analyst Ratings Breakdown

Latest RVNC, MDGL, HRMY, GBIO, and STOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/6/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$49.00 ➝ $49.00
5/2/2025	MDGL Madrigal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$441.00 ➝ $458.00
5/2/2025	MDGL Madrigal Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$422.00 ➝ $460.00
5/2/2025	MDGL Madrigal Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$394.00 ➝ $420.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GBIO Generation Bio	$19.89M	1.17	N/A	N/A	$1.29 per share	0.27
HRMY Harmony Biosciences	$714.73M	2.58	$2.94 per share	10.91	$11.56 per share	2.78
MDGL Madrigal Pharmaceuticals	$317.38M	20.88	N/A	N/A	$34.59 per share	8.63
RVNC Revance Therapeutics	$234.04M	1.63	N/A	N/A	($1.73) per share	-2.11
STOK Stoke Therapeutics	$190.91M	3.28	N/A	N/A	$4.32 per share	2.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GBIO Generation Bio	-$131.67M	-$1.08	N/A	N/A	N/A	-292.92%	-75.84%	-30.40%	8/6/2025 (Estimated)
HRMY Harmony Biosciences	$145.49M	$2.62	12.25	10.32	0.48	20.53%	24.32%	15.92%	8/5/2025 (Estimated)
MDGL Madrigal Pharmaceuticals	-$465.89M	-$18.05	N/A	N/A	N/A	-123.38%	-50.54%	-37.19%	8/6/2025 (Estimated)
RVNC Revance Therapeutics	-$323.99M	-$1.93	N/A	N/A	N/A	-74.67%	N/A	-37.22%	8/6/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.79	14.54	N/A	N/A	26.33%	19.08%	15.72%	8/5/2025 (Estimated)

Latest RVNC, MDGL, HRMY, GBIO, and STOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	GBIO Generation Bio	-$0.25	-$0.22	+$0.03	-$0.22	$1.70 million	$8.72 million
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
5/1/2025	Q1 2025	MDGL Madrigal Pharmaceuticals	-$3.62	-$3.32	+$0.30	-$3.32	$112.79 million	$137.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GBIO Generation Bio	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RVNC Revance Therapeutics	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GBIO Generation Bio	N/A	8.43	8.43
HRMY Harmony Biosciences	0.22	3.67	3.63
MDGL Madrigal Pharmaceuticals	0.17	5.91	5.58
RVNC Revance Therapeutics	N/A	4.12	3.05
STOK Stoke Therapeutics	N/A	8.41	8.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GBIO Generation Bio	95.22%
HRMY Harmony Biosciences	86.23%
MDGL Madrigal Pharmaceuticals	98.50%
RVNC Revance Therapeutics	97.70%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
GBIO Generation Bio	21.80%
HRMY Harmony Biosciences	23.60%
MDGL Madrigal Pharmaceuticals	21.50%
RVNC Revance Therapeutics	5.10%
STOK Stoke Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GBIO Generation Bio	150	67.04 million	52.42 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	43.87 million	Optionable
MDGL Madrigal Pharmaceuticals	90	22.20 million	17.43 million	Optionable
RVNC Revance Therapeutics	500	104.39 million	99.07 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	49.41 million	Optionable

RVNC, MDGL, HRMY, GBIO, and STOK Headlines

Recent News About These Companies

Zebra crossings to be installed outside TWO schools on same Stoke-on-Trent road

July 5 at 11:14 PM | msn.com

Stoke-on-Trent-based Prohire Limited falls into administration

July 5 at 11:14 PM | bbc.co.uk

Maksym Talovierov makes 'cold nights' promise with brilliant Stoke City statement

July 5 at 11:14 PM | msn.com

DONE DEAL: Stoke snap up Man City striker Mubama

July 5 at 11:14 PM | tribalfootball.comT

Five Guys to open first Stoke-on-Trent restaurant

July 5 at 11:14 PM | msn.com

Mubama set for Stoke loan switch

July 5 at 11:14 PM | sports.yahoo.com

Porch pirates target Stoke-on-Trent as parcels swiped from doorsteps

July 3 at 6:34 AM | uk.news.yahoo.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $23.20 Average Target Price from Brokerages

July 3 at 2:41 AM | americanbankingnews.com

Stoke City on brink of agreement for Plymouth Argyle record signing

July 2, 2025 | msn.com

Stockley named Stoke's new academy manager

July 2, 2025 | msn.com

Stoke Therapeutics' (STOK) "Buy" Rating Reaffirmed at Needham & Company LLC

July 1, 2025 | marketbeat.com

Michelin’s Stoke-on-Trent plant set to lower CO2 emissions with tyre reprocessing site

July 1, 2025 | thebusinessdesk.comT

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Buy" from Analysts

June 30, 2025 | marketbeat.com

STOK Stoke Therapeutics, Inc. - Seeking Alpha

June 29, 2025 | seekingalpha.com

Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Legend Biotech (LEGN)

June 28, 2025 | theglobeandmail.com

Stoke-on-Trent bungalow could be turned into children's home

June 28, 2025 | msn.com

Stoke City confirm new coach appointment as pre-season starts

June 27, 2025 | msn.com

Traditional Stoke-on-Trent pub reopens for the first time since Covid

June 27, 2025 | stokesentinel.co.ukS

Stoke Therapeutics (NASDAQ:STOK) Trading Down 3.5% - Here's Why

June 26, 2025 | marketbeat.com

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 17, 2025 | businesswire.com

STOK FY2025 EPS Forecast Lowered by Cantor Fitzgerald

June 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVNC, MDGL, HRMY, GBIO, and STOK Company Descriptions

Generation Bio NASDAQ:GBIO

$0.35 +0.01 (+2.99%)

Closing price 07/3/2025 03:42 PM Eastern

Extended Trading

$0.35 0.00 (0.00%)

As of 07/3/2025 04:43 PM Eastern

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Harmony Biosciences NASDAQ:HRMY

$32.09 -0.02 (-0.06%)

Closing price 07/3/2025 03:51 PM Eastern

Extended Trading

$32.18 +0.09 (+0.28%)

As of 07/3/2025 04:01 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Madrigal Pharmaceuticals NASDAQ:MDGL

$298.48 -1.67 (-0.55%)

Closing price 07/3/2025 03:39 PM Eastern

Extended Trading

$298.48 0.00 (0.00%)

As of 07/3/2025 04:09 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Revance Therapeutics NASDAQ:RVNC

$3.65 0.00 (0.00%)

As of 02/6/2025

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Stoke Therapeutics NASDAQ:STOK

$11.48 -0.07 (-0.56%)

Closing price 07/3/2025 03:52 PM Eastern

Extended Trading

$11.48 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time